Cargando…

Why responses to immune checkpoint inhibitors are heterogeneous in head and neck cancers: Contributions from tumor-intrinsic and host-intrinsic factors

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment including in head and neck squamous cell carcinomas (HNSCCs); however, only a fraction of HNSCC patients respond to ICI, whereas the majority fail to do so. The mechanisms underlying such variable responses remain incompletely...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Zhangguo, John, Jessy, Wang, Jing H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623029/ https://www.ncbi.nlm.nih.gov/pubmed/36330485 http://dx.doi.org/10.3389/fonc.2022.995434

Ejemplares similares

Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
por: dos Santos, Lucas V., et al.
Publicado: (2021)

Rational Combinations of Targeted Therapy and Immune Checkpoint Inhibitors in Head and Neck Cancers
por: Chai, Annie Wai Yeeng, et al.
Publicado: (2022)

Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma
por: Manukian, Gregor, et al.
Publicado: (2019)

Host response to immune checkpoint inhibitors contributes to tumor aggressiveness
por: Khononov, Irina, et al.
Publicado: (2021)

What’s in a name? Why these proteins are intrinsically disordered: Why these proteins are intrinsically disordered
por: Dunker, A. Keith, et al.
Publicado: (2013)

Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors
por: Arribas, Lorena, et al.
Publicado: (2021)

Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion
por: Dong, Peixin, et al.
Publicado: (2018)

Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy
por: Chye, Adrian, et al.
Publicado: (2022)

Hepatocellular Carcinoma Intrinsic Cell Death Regulates Immune Response and Prognosis
por: De Re, Valli, et al.
Publicado: (2022)

Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in TCR repertoire and distinct T cell activation states in responding versus non-responding tumors
por: John, Jessy, et al.
Publicado: (2022)

A diversity outbred F1 mouse model identifies host-intrinsic genetic regulators of response to immune checkpoint inhibitors
por: Hackett, Justin B., et al.
Publicado: (2022)

Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation
por: Lin, Wanzun, et al.
Publicado: (2023)

Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers
por: Trono, Paola, et al.
Publicado: (2017)

The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
por: Nicoś, Marcin, et al.
Publicado: (2020)

Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors
por: Reul, Johanna, et al.
Publicado: (2019)

Obesity and Cancer Metabolism: A Perspective on Interacting Tumor–Intrinsic and Extrinsic Factors
por: Doerstling, Steven S., et al.
Publicado: (2017)

Intrinsic and Extrinsic Modulators of the Epithelial to Mesenchymal Transition: Driving the Fate of Tumor Microenvironment
por: D'Angelo, Edoardo, et al.
Publicado: (2020)

Regulation of Intrinsic Functions of PD-L1 by Post-Translational Modification in Tumors
por: Nihira, Naoe Taira, et al.
Publicado: (2022)

A Retrospective Analysis of a Cohort of Patients Treated With Immune Checkpoint Blockade in Recurrent/Metastatic Head and Neck Cancer
por: Bila, Michel, et al.
Publicado: (2022)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021)

Diffuse intrinsic pontine glioma: poised for progress
por: Warren, Katherine E.
Publicado: (2012)

Genomic Insights into Diffuse Intrinsic Pontine Glioma
por: Lapin, Danielle H., et al.
Publicado: (2017)

Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer
por: Kok, Victor C.
Publicado: (2020)

Invaders Exposed: Understanding and Targeting Tumor Cell Invasion in Diffuse Intrinsic Pontine Glioma
por: Kluiver, T. A., et al.
Publicado: (2020)

Next-generation sequencing identifies CDKN2A alterations as prognostic biomarkers in recurrent or metastatic head and neck squamous cell carcinoma predominantly receiving immune checkpoint inhibitors
por: Xue, Liqiong, et al.
Publicado: (2023)

Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors
por: Zhang, Lin, et al.
Publicado: (2022)

Integrating Intrinsic Radiosensitivity and Immune Status for Predicting Benefits of Radiotherapy in Head and Neck Squamous Cell Carcinoma
por: Sun, Chuyao, et al.
Publicado: (2021)

Intrinsic Differences in Immune Checkpoint Inhibitor-Induced Myocarditis: A Retrospective Analysis of Real World Data
por: Lei, Yanna, et al.
Publicado: (2022)

Recombinant immunotoxin induces tumor intrinsic STING signaling against head and neck squamous cell carcinoma
por: Xie, Guiqin, et al.
Publicado: (2023)

Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
por: Litchfield, Kevin, et al.
Publicado: (2021)

Case report: A case of heterogeneity of the antitumor response to immune checkpoint inhibitors in a patient with relapsed hepatocellular carcinoma
por: Bao, Yingying, et al.
Publicado: (2022)

Pre-Clinical Models of Diffuse Intrinsic Pontine Glioma
por: Misuraca, Katherine L., et al.
Publicado: (2015)

A 14-Marker Multiplexed Imaging Panel for Prognostic Biomarkers and Tumor Heterogeneity in Head and Neck Squamous Cell Carcinoma
por: Mitsuda, Junichi, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor-induced Fanconi Syndrome
por: Farid, Saira, et al.
Publicado: (2020)

STING is an intrinsic checkpoint inhibitor that restrains the T(H)17 cell pathogenic program
por: Damasceno, Luis Eduardo Alves, et al.
Publicado: (2022)

Strategies for the Construction of Mouse Models With Humanized Immune System and Evaluation of Tumor Immune Checkpoint Inhibitor Therapy
por: Guo, Wenwen, et al.
Publicado: (2021)

Improvement of Antitumor Therapies Based on Vaccines and Immune-Checkpoint Inhibitors by Counteracting Tumor-Immunostimulation
por: Chiarella, Paula, et al.
Publicado: (2018)

Tumor-Intrinsic Nuclear β-Catenin Associates with an Immune Ignorance Phenotype and a Poorer Prognosis in Head and Neck Squamous Cell Carcinomas
por: Sánchez-Canteli, Mario, et al.
Publicado: (2022)

Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
por: Oliva, M, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_p0aca6msea6as2b4cq6hudojs7